Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia - ScienceDirect
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study | Leukemia
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL | NEJM
![PDF] Initial treatment of CLL: integrating biology and functional status. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/7b412b923e9a2dd4366134630d23613c24240fc9/19-Table2-1.png "PDF] Initial treatment of CLL: integrating biology and functional status. | Semantic Scholar")
PDF] Initial treatment of CLL: integrating biology and functional status. | Semantic Scholar
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial | Haematologica
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia | NEJM
Ongoing or planned phase 3 trials in the first-line setting for CLL | Download Table
IVO vs IO Phase 3 Trial of the Impact of Adding Venetoclax to Ibrutinib and Obinutuzumab in CLL
Managing CLL With BTK Inhibitors - ppt download
Frontline Management of CLL in 2021 | JCO Oncology Practice
Cancer and Leukemia Group B (CALGB)/Alliance 90203 trial (NCT00430183)... | Download Scientific Diagram
Clinical Trials – New Developments in Lymphoma
Reaping the Rewards of Innovative Care in CLL: From Targeted Strategies to Cellular Therapy
Alliance for Clinical Trials in Oncology on X: "Matthew Wieduwilt, MD, PhD @UCSDHealth leads @ALLIANCE_org A041703, an #immunotherapy trial for treating patients with acute lymphoblastic #leukemia that's newly diagnosed, has come back,
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study | Leukemia
Zanubrutinib Wins in First-Line CLL for Older Patients | MedPage Today
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial - The Lancet Oncology
Targeted therapy for the most common leukemia | MD Anderson Cancer Center
ALLIANCE A041202 - Study Design | IMBRUVICA® (ibrutinib) HCP
Chronic lymphocytic leukemia treatment algorithm 2022 | Blood Cancer Journal
Ibrutinib and Rituximab (IR) is Superior to Chemo-immunotherapy (CIT) in CLL: Big News, or is it really? And did they get it right? - CLL Society
Cancers | Free Full-Text | Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option
A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia -
